Abstract
We present a framework for simulating cross-sectional or longitudinal biomarker data sets from neurodegenerative disease cohorts that reflect the temporal evolution of the disease and population diversity. The simulation system provides a mechanism for evaluating the performance of data-driven models of disease progression, which bring together biomarker measurements from large cross-sectional (or short term longitudinal) cohorts to recover the average population-wide dynamics. We demonstrate the use of the simulation framework in two different ways. First, to evaluate the performance of the Event Based Model (EBM) for recovering biomarker abnormality orderings from cross-sectional datasets. Second, to evaluate the performance of a differential equation model (DEM) for recovering biomarker abnormality trajectories from short-term longitudinal datasets. Results highlight several important considerations when applying data-driven models to sporadic disease datasets as well as key areas for future work. The system reveals several important insights into the behaviour of each model. For example, the EBM is robust to noise on the underlying biomarker trajectory parameters, under-sampling of the underlying disease time course and outliers who follow alternative event sequences. However, the EBM is sensitive to accurate estimation of the distribution of normal and abnormal biomarker measurements. In contrast, we find that the DEM is sensitive to noise on the biomarker trajectory parameters, resulting in an over estimation of the time taken for biomarker trajectories to go from normal to abnormal. This over estimate is approximately twice as long as the actual transition time of the trajectory for the expected noise level in neurodegenerative disease datasets. This simulation framework is equally applicable to a range of other models and longitudinal analysis techniques.
Highlights
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), present increasing social and economic costs
We performed a stability analysis of the Event Based Model (EBM) to test how robust the model is to different types of heterogeneity that are likely to exist in sporadic AD datasets
This is because cognitively normal subjects in Alzheimer’s Disease Neuroimaging Initiative (ADNI) may originate from a range of underlying time points along the biomarker trajectories
Summary
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), present increasing social and economic costs. Biomarkers have been developed that allow the presence and progression of these pathologies to be measured in vivo. Such biomarkers include cerebrospinal fluid (CSF) measures of proteins implicated in disease pathogenesis, structural magnetic resonance imaging (MRI) measures of regional volume changes, positron emission tomography (PET) measures of hypometabolism or abnormal protein deposition, and cognitive test scores. Recent multi-centre collaborations, such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) for AD, the Parkinson Progression Marker Initiative (PPMI) for PD, and the Track-HD study for HD, collect a diverse set of biomarker data from large cohorts. As a result, understanding of the longitudinal evolution of biomarkers in neurodegenerative diseases remains largely hypothetical (Aisen et al, 2010; Frisoni et al, 2010; Jack et al, 2010)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.